TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2378593

Group type: EXPERIMENTAL
Intervention: TENS (Group A)
Number of subjects: 121

Group type: COMPARATOR
Intervention: ENTONOX (Group B)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TENS (Group C)
Number of subjects: 121

Group type: COMPARATOR
Intervention: ENTONOX (Group D)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 121

Group type: COMPARATOR
Intervention: ENTONOX
Number of subjects: 121
Study: 760446

Group type: EXPERIMENTAL
Intervention: Continuous heparin therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intermittent heparin therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overall group (both therapies)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Soft-tissue trauma patients
Number of subjects: 80
Study: 31226195

Group type: EXPERIMENTAL
Intervention: Equicrestal level (E group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supracrestal level (SP group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (E and SP)
Number of subjects: 30
Study: 29059635

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg, once daily)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 526
Study: 25952455

Group type: EXPERIMENTAL
Intervention: Bag Valve Mask (BVM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 20
Study: 23168347

Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Knowledge-based intervention
Number of subjects: 71
Study: 22065255

Group type: COMPARATOR
Intervention: Standard Medical Management (SMM)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: SMM plus opioid dependence counseling
Number of subjects: 653

Group type: COMPARATOR
Intervention: Extended buprenorphine-naloxone treatment (week 12)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: SMM plus opioid dependence counseling during extended treatment
Number of subjects: 653

Group type: COMPARATOR
Intervention: Postmedication follow-up (week 24)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Postmedication follow-up (week 24) with counseling
Number of subjects: 653
Study: 19321573

Group type: EXPERIMENTAL
Intervention: Vitamin D (83 microg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 17482105

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 15243011

Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11940618

Group type: EXPERIMENTAL
Intervention: Paratendinous nailing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transtendinous nailing
Number of subjects: 50
Study: 9864127

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR) with Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Balanced salt solution (BSS Plus) with Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline solution (NSS) with Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR) without Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS Plus) without Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline solution (NSS) without Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Morgan therapeutic lens (MTL)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ocular irrigation solutions (LR, BSS Plus, NSS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ocular irrigation with MTL
Number of subjects: 61
Study: 8919570

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening (various modalities); specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer simulation model; specific details on intervention not available.
Number of subjects: 0
Study: 2191990

Group type: EXPERIMENTAL
Intervention: Inhaled bitolterol (three puffs, 1110 micrograms)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Albuterol (two puffs, 180 micrograms)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15186986

Group type: EXPERIMENTAL
Intervention: Success feedback condition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Failure feedback condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive beliefs (expectancy and attribution)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expectancy and luck
Number of subjects: 120
Study: 31132779

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicines (CAMs)
Number of subjects: 200
Study: 28085022

Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods (80 g/day)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Refined-grain (RG) foods (80 g/day)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both WG and RG groups
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods
Number of subjects: 179
Study: 25752438

Group type: EXPERIMENTAL
Intervention: 100 mg VIA-2291 for 24 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 52
Study: 23447044

Group type: EXPERIMENTAL
Intervention: Myrtol® 300 mg 4 times daily
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Myrtol®
Number of subjects: 413
Study: 21145264

Group type: EXPERIMENTAL
Intervention: AorfixTM endovascular stent graft
Number of subjects: 30
Study: 19268886

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of imaging methods
Number of subjects: 18
Study: 17289683

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (ET)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Blind embryo transfer (ET)
Number of subjects: 300
Study: 15058377

Group type: EXPERIMENTAL
Intervention: Atrisorb barrier (n = 22; group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resolut XT barrier (n = 18; group B)
Number of subjects: 30
Study: 11279374

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (Group T)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 1.5 g/kg (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 20 g (Group S)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NaCl 5 ml (Control Group F)
Number of subjects: 80
Study: 9444564

Group type: EXPERIMENTAL
Intervention: 200 lux dim white light exposure between 2400 hr and 0100 hr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 lux dim white light exposure between 2400 hr and 0100 hr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intensity light exposure
Number of subjects: 0
Study: 8193000

Group type: EXPERIMENTAL
Intervention: Saphenous vein patching
Number of subjects: 129

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 129

Group type: COMPARATOR
Intervention: Comparison of patch vs primary closure
Number of subjects: 129
Study: 3249839

Group type: EXPERIMENTAL
Intervention: 30 mg aminophylline aerosol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo aerosol
Number of subjects: 8
Study: 29309737

Group type: EXPERIMENTAL
Intervention: green banana biomass alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: green banana biomass plus sodium picosulfate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: green banana biomass plus PEG 3350 with electrolytes
Number of subjects: 80

Group type: COMPARATOR
Intervention: PEG 3350 with electrolytes alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: sodium picosulfate alone
Number of subjects: 80
Study: 28225446

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CT) alone
Number of subjects: 270

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 270

Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy (CRT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 270
Study: 27084997

Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg in healthy subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg in patients with mild HI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg in patients with moderate HI
Number of subjects: 18
Study: 23034875

Group type: EXPERIMENTAL
Intervention: Medtronic electrodes (group M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Osypka electrodes (group O)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both electrode types
Number of subjects: 60
Study: 21613810

Group type: EXPERIMENTAL
Intervention: HbA1c value of 6.9% for diagnosing diabetes mellitus
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: HbA1c cut-off points of 6.1%
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: HbA1c as an independent risk factor
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Increase in R wave in lead aVL
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: HbA1c as a predictor of cardiovascular disease
Number of subjects: 687
Study: 21141286

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment nonresponders
Number of subjects: 0
Study: 17581943

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by the Geriatric Depression Scale (GDS‐15)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS‐15)
Number of subjects: 413
Study: 16371745

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blockade)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 11905085

Group type: EXPERIMENTAL
Intervention: Dunaliella (natural)‐beta‐carotene supplementation for 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (without supplementation)
Number of subjects: 15
Study: 9469674

Group type: EXPERIMENTAL
Intervention: G-CSF administration 24 hours after chemotherapy (standard arm)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: G-CSF administration when ANC < 1000/mm3 (delayed arm)
Number of subjects: 25
Study: 10150756

Group type: EXPERIMENTAL
Intervention: Maxima 1380 oxygenator
Number of subjects: 32

Group type: COMPARATOR
Intervention: Maxima Plus oxygenator
Number of subjects: 32
Study: 2570601

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (A100)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (P40)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (P1)
Number of subjects: 5
Study: 327585

Group type: EXPERIMENTAL
Intervention: tolmetin (900 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: aspirin (4 500 mg daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: tolmetin
Number of subjects: 55
Study: 31242669

Group type: EXPERIMENTAL
Intervention: Enzyme-containing dentifrices (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Conventional dentifrices containing 1450 ppm fluoride (group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Natural dentifrices containing no chemical agent (group 3)
Number of subjects: 42
Study: 29123255

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment
Number of subjects: 871

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 871
Study: 27132052

Group type: EXPERIMENTAL
Intervention: Hysteroscopy with treatment of detected intracavitary abnormalities before starting IVF (n=373)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Immediate start of IVF treatment (n=377)
Number of subjects: 750
Study: 24379449

Group type: EXPERIMENTAL
Intervention: Massage therapy (MT), 30 min twice a week for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonmassage sham treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Massage therapy (MT)
Number of subjects: 36
Study: 21940484

Group type: EXPERIMENTAL
Intervention: G200 (200 mg/dL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: G100 (100 mg/dL)
Number of subjects: 29
Study: 19171204

Group type: EXPERIMENTAL
Intervention: Progressive strength training
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study: 18021526

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 25
Study: 15885046

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.18-0.36 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16841622

Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg once daily
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Divided doses of modafinil 300 mg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg (200/200 mg) in children weighing >= 30 kg
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Modafinil 200/100 mg
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 10370786

Group type: EXPERIMENTAL
Intervention: High serum IL-10 levels (elevated > or = 10 pg/ml)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal serum IL-10 levels (below 10 pg/ml)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High serum IL-10 levels in Ann Arbor stage III or IV
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal serum IL-10 levels in Ann Arbor stage III or IV
Number of subjects: 101
Study: 8880049

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2068426

Group type: EXPERIMENTAL
Intervention: Liver transplant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 6302612

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intravenous daily dosage for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefuroxime (three times daily for 5 days)
Number of subjects: 30
Study: 31000792

Group type: EXPERIMENTAL
Intervention: Blood mercury levels
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Blood lead levels
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Blood cadmium levels
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Blood manganese levels
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Blood selenium levels
Number of subjects: 20000
Study: 30066731

Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 0
Study: 27702718

Group type: EXPERIMENTAL
Intervention: Multivitamin with vitamin D (cholecalciferol 12,000 IU/week)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Renal multivitamin without vitamin D
Number of subjects: 76
Study: 24889794

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Radical cystectomy alone
Number of subjects: 114
Study: 22284243

Group type: EXPERIMENTAL
Intervention: Active patients (low or moderate-intensity physical activities >2 h/week)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Active patients
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 247
Study: 20219000

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (Group B, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% and Levobupivacaine 0.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L)
Number of subjects: 45
Study: 17579949

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: One-lung ventilation (OLV)
Number of subjects: 60
Study: 16480242

Group type: COMPARATOR
Intervention: Conventional trauma writing
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Religious trauma writing
Number of subjects: 177
Study: 12050277

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/d for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU/d for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10585241

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (implicit memory tests without midazolam)
Number of subjects: 0
Study: 8943604

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg intravenously
Number of subjects: 67

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 67
Study: 1882698

Group type: EXPERIMENTAL
Intervention: Lithium plus carbamazepine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lithium alone
Number of subjects: 16
Study: 31628006

Group type: EXPERIMENTAL
Intervention: Asthma education intervention (home visits and education on asthma management)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 901
Study: 30928841

Group type: EXPERIMENTAL
Intervention: 8-week selective corrective exercises program
Number of subjects: 30
Study: 27925214

Group type: EXPERIMENTAL
Intervention: Chronic administration of reboxetine (RBX) 8 mg/day with anodal tDCS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic administration of reboxetine (RBX) 8 mg/day with cathodal tDCS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single dose of reboxetine (RBX) 8 mg with anodal tDCS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single dose of reboxetine (RBX) 8 mg with cathodal tDCS
Number of subjects: 16
Study: 25964261

Group type: EXPERIMENTAL
Intervention: Automated Self‐Administered 24‐Hour Recall (ASA24)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Interviewer‐administered, Automated Multiple‐Pass Method (AMPM)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: ASA24
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: ASA24/AMPM
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: ASA24/ASA24
Number of subjects: 1081

Group type: COMPARATOR
Intervention: AMPM/AMPM
Number of subjects: 1081
Study: 24127181

Group type: EXPERIMENTAL
Intervention: Dedicated Education Units (DEUs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional clinical education model
Number of subjects: 0
Study: 21704241

Group type: EXPERIMENTAL
Intervention: 105-mg fenofibric acid (fasted)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 145-mg fenofibrate (fasted)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 105-mg fenofibric acid (fed)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 145-mg fenofibrate (fed)
Number of subjects: 54
Study: 20015402

Group type: EXPERIMENTAL
Intervention: PermaNet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olyset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DuraNet
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLINs perceived not to prevent mosquito bites
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLINs allowing a pleasant night's sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: LLINs with a soft texture
Number of subjects: 0
Study: 17337289

Group type: EXPERIMENTAL
Intervention: EDTA or citrate plasma samples
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serum samples
Number of subjects: 60
Study: 15155407

Group type: EXPERIMENTAL
Intervention: Cough plate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moistened cough swab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dry cough swab
Number of subjects: 20
Study: 11319885

Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin 0.3 IU/kg/day) for 5 days before laparotomy and aortic cross-clamping for 30 min followed by lower torso revascularization for 2 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (laparotomy only)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IR (laparotomy with infrarenal cross-clamping for 30 min followed by lower torso revascularization for 2 h)
Number of subjects: 18
Study: 9389287

Group type: EXPERIMENTAL
Intervention: Peanut protein (doses ranging from 10 microg to 50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 14
Study: 8189741

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3580729

Group type: EXPERIMENTAL
Intervention: Endurance (2 sets of 15 repetition maximum [RM])
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Explosive (1 set of 15 RM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength 1 (3 sets of 6 RM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength 2 (1 set of 10 RM twice weekly and 1 set of 3 RM once weekly)
Number of subjects: 45
Study: 31039759

Group type: EXPERIMENTAL
Intervention: Ethenox (ethanol 40% v/v-enoxaparin 1000 U/mL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) or citrate 4% w/v
Number of subjects: 200
Study: 29093246

Group type: EXPERIMENTAL
Intervention: Lumbrokinase in combination with low molecular heparin and sequential warfarin (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (low molecular heparin and sequential warfarin, n=30)
Number of subjects: 60
Study: 26344824

Group type: EXPERIMENTAL
Intervention: Combination framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U.S. postal mail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Organ donor, organ recipient, and waiting list narratives
Number of subjects: 0